Aclarion Publishes 2026 Shareholder Letter from the Chairman
MWN-AI** Summary
Aclarion, Inc. (Nasdaq: ACON, ACONW) has released its 2026 Shareholder Letter from Chairman Jeff Thramann, highlighting the company’s progress and strategic outlook. Aclarion, a healthcare tech firm specializing in biomarkers and AI algorithms to pinpoint chronic low back pain, reported a strong financial position with a cash runway projected into 2028. The company intends to reach significant clinical milestones, including an internal readout of its 300-patient CLARITY trial by the end of Q3 2026 and plans to disclose early interim results publicly in Q4.
Thramann emphasized Aclarion's commitment to shareholder value, noting that there will be no capital raises before achieving these value-enhancing milestones. The company has terminated its At-the-Market (ATM) program and its Equity Line of Credit (ELOC) expired at the end of December 2025, ensuring that resources are utilized efficiently to support ongoing operations without additional fundraising pressures.
Aclarion stands out as a new generation MedTech innovator, delivering its solutions through a cloud-based platform, Nociscan, which leverages Magnetic Resonance Spectroscopy (MRS) to help physicians distinguish between painful and non-painful discs in the lumbar spine. This cloud-native approach facilitates impressive software-level gross margins and rapid scalability without the constraints of traditional manufacturing.
Going forward, Aclarion plans to enhance its visibility among institutional healthcare investors and the broader medical community, striving to create awareness and education around its innovative technology. The full shareholder letter and further details about Aclarion’s strategies are accessible on the company's investor relations website. As Aclarion progresses through 2026, it will focus on aligning its clinical advancements with shareholder interests and corporate growth.
MWN-AI** Analysis
Aclarion, Inc. (Nasdaq: ACON) recently released its 2026 Shareholder Letter, revealing a robust financial standing and a strategic plan focusing on pivotal clinical advancements. The company’s decision to maintain a cash runway extending into 2028, combined with the termination of an At-the-Market (ATM) offering and an Expiring Line of Credit (ELOC), positions it favorably to mitigate unnecessary dilution before reporting initial data from its CLARITY trial slated for late Q3 and Q4 of 2026.
For investors, this strengthened balance sheet presents a key reason to consider Aclarion’s stock. The absence of immediate capital raises offers reassurances regarding shareholder value, especially as the company anticipates significant catalysts from the CLARITY trial, which involves innovative biomarker assessments for chronic low back pain management—a substantial market segment.
As Aclarion evolves as a software-native MedTech innovator, its cloud-based Nociscan platform promises not just scalability but also enhanced revenue models characterized by high gross margins typical of software businesses. This positions Aclarion as an attractive alternative to traditional MedTech firms, which often incur heavy manufacturing costs and inventory risks.
Moving forward, investors should keep an eye on the upcoming trial results, as positive outcomes could substantially elevate Aclarion's stock value. The well-thought-out communication strategy targeting institutional investors and healthcare professionals underlines the company’s commitment to transparency and relationship-building, which can enhance market sentiment and attract additional interest.
In summary, Aclarion warrants attention given its strategic operational focus, financial health, and potential for significant market impact through its pioneering healthcare solutions. Investors should monitor clinical trial developments closely, as they could serve as key indicators of future performance.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Company anticipates no capital raises prior to expected value enhancing catalysts
- Cash runway into 2028
- ATM terminated in early 2025 and ELOC expired December 31, 2025
BROOMFIELD, Colo., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the release of its 2026 Shareholder Letter from the Chairman. The letter outlines significant clinical, financial, and operational priorities as the company advances toward an expected initial internal readout of its 300-patient CLARITY trial at the end of Q3 and an expected public disclosure of early interim results in Q4 of 2026.
“Aclarion enters 2026 with a strengthened balance sheet, a scalable software-native business model, and a clear path to an initial readout on our CLARITY trial,” said Jeff Thramann, Executive Chairman of Aclarion. “With cash runway into 2028 and a clean capital structure, we are fully funded to deliver this important clinical milestone. Our focus is on ensuring that the value created by our early data accrues directly to our existing shareholders as we continue advancing a technology that provides physicians with objective biochemical insights to support better decision-making for patients suffering from chronic low back pain.”
The company highlighted its strengthened financial position. Following recent financings, the company reiterated it now has a cash runway into 2028, providing the resources needed to complete the CLARITY trial and operate through the initial data readout without raising additional capital. To reinforce this commitment to shareholder alignment, Aclarion no longer has an ATM in place and its ELOC expired at the end of 2025. The Company currently has 2,882,371 shares outstanding on a fully diluted basis and will not be putting a new ATM or ELOC in place until after it reports on the initial interim CLARITY results.
Aclarion also emphasized its position as part of a new generation of software-native MedTech innovators that, unlike traditional device companies, deliver its solution entirely through the cloud. This enables software-level gross margins, rapid scalability, and continuous algorithmic improvement without manufacturing or inventory constraints.
In 2026, the company will be executing a structured investor-awareness strategy focused on institutional healthcare investors, physician-led clinical education, and increased visibility in financial and medical media.
The full 2026 Shareholder Letter is available on the company’s website at: https://investors.aclarion.com/news
For more News from Aclarion, please visit: Latest News
To find a Nociscan center, view our site map here.
For more information on Nociscan, please email: [email protected]
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Forward-looking statements in this release include, among others, statements regarding the enrollment of patients in our ongoing clinical trials, the expected initial internal readout of its 300-patient CLARITY trial at the end of Q3 2026 and an expected public disclosure of early interim results in Q4 of 2026, having a cash runway into 2028, providing the resources needed to complete the CLARITY trial and operate through the initial data readout without raising additional capital, the Company will not be putting a new ATM or ELOC in place until after it reports on the initial interim CLARITY results, the potential benefits of our Nociscan technology, and the Company’s plans for future regulatory and commercialization activities. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
[email protected]
Media Contacts:
Jessica Starman
[email protected]
FAQ**
How does Aclarion Inc. plan to leverage the anticipated data from the CLARITY trial to enhance the value of Aclarion Inc. Warrant ACONW for shareholders in light of the expected interim results in Q4 2026?
Given the absence of additional capital raises prior to the CLARITY trial readout, how does Aclarion Inc. intend to sustain its operations and support the growth of Aclarion Inc. Warrant ACONW through to 2028?
What specific steps is Aclarion Inc. taking to increase investor awareness of its technology, and how might this strategy impact the trading performance of Aclarion Inc. Warrant ACONW in the healthcare investment community?
How does Aclarion Inc.'s cloud-based approach differentiate it from traditional MedTech companies, and what implications does this have for the potential future value of Aclarion Inc. Warrant ACONW after the CLARITY trial results are published?
**MWN-AI FAQ is based on asking OpenAI questions about Aclarion Inc. (NASDAQ: ACON).
NASDAQ: ACON
ACON Trading
3.86% G/L:
$2.69 Last:
33,729 Volume:
$2.68 Open:
